Veröffentlichungen
Chronologische Liste
1. Sutor AH, Pollmann H, Arends P. Intranasal application of D.D.A.V.P. in severe haemophilia. The Lancet 1978;25;1(8061):446.
2. Sutor AH, Pollmann H, Arends P. Intranasal hemophilia therapy with a vasopressin analog. Monatsschrift Kinderheilkunde 1979;127(5):281-3.
3. Schmitz-Huebner U, Balleisen L, Arends P, Pollmann H, Sutor AH. DDAVP-induced changes of factor VIII-related activities and bleeding time in patients with von Willebrand's syndrome. Haemostasis 1980;9(4):204-213.
4. Sutor AH, Pancochar H, Niederhoff H, Pollmann H, Hilgenberg F, Palm D, Künzer W. Vitamin K deficiency hemorrhages in 4 exclusively breast-fed infants 4 to 6 weeks of age. Deutsche Medizinische Wochenschrift 1983;108(43):1635-1639.
5. Sutor AH, Wulff J, Ritter J, Pollmann H, Schellong G. Hemostasis and fibrinolysis in acute lymphoblastic leukemia (ALL) in childhood - analysis of life-threatening bleeding. Klinische Pädiatrie 1984;196(3):166-173.
6. Ritter J, Pauly T, Pollmann H. Salmonella osteoarthritis in hemophilia A. Monatsschrift Kinderheilkunde 1986;134(9):701-702.
7. Creutzig U, Stahnke K, Pollmann H, Sutor A, Ritter J, Budde M, Schellong G. The problem of early death in childhood AML. Haematology and Blood Transfusion 1987;30:524-529.
8. Erlemann R, Pollmann H, Reiser M, Almeida P, Peters PE. Staging of hemophilic osteoarthropathy using the Pettersson score. A study of 40 children and adolescents. RöFo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der Nuklearmedizin 1987;147(5):521-526.
9. Pollmann H. The frequency of joint bleeding episodes as a leading parameter to adjust replacement therapy in haemophilia. Replacement Therapy in Haemophilia – Problems and Solutions, 1988:45-49.
10. Boos J, Pollmann H, Dominick HC. Vitamin K-dependent coagulation parameters during the first six days of life: incidence of PIVKA II in newborns. Pediatric Hematology and Oncology 1989;6(2):113-119.
11. Erlemann R, Pollmann H, Adolph J, Peters PE. Hemophilic osteoarthropathy with special reference to the elbow joint. Der Radiologe 1990;30(3):116-123. (Review)
12. Erlemann R, Pollmann H, Vestring T, Peters PE. The MR tomography of hemophilic osteoarthropathy with special reference to the synovial and chondrogenic changes. RöFo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der Nuklearmedizin 1992;156(3):270-6.
13. Pollmann H, Jürgens H. Transmission of hepatitis in haemophiliacs. The Lancet 1992;340(8822):793.
14. Pollmann H. Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia. Infusionstherapie und Transfusionsmedizin 1994;21 Suppl 1:80-3. (Review)
15. Pollmann H, Linnenbecker S. The frequency of joint bleedings in early childhood in patients with severe haemophilia. Haemophilia 1996;2: (suppl 1), Abstract 67.
16. Pollmann H, Richter H. Prevalence of factor VIII inhibitors with clinical relevance in haemophilia treatment. Haemophilia 1996;2: (suppl 1), Abstract 68.
17. Pollmann H, Richter H, Kahl B, Peters B. 15 years experience with virus safety of pasteurized factor VIII concentrates in Germany. Haemophilia 1996;2: (suppl 1), abstract 91.
18. Pollmann H. A haemophilia B patient with complete factor IX gene deletion and a high titer antibody against F IX In: Haemophilia, 1996;2 (suppl 1), Abstract 274.
19. Elödi S, Pollmann H, Kotitschke R, Dichtelmüller H, Rudnick D, Kloft M. Factor VIII inhibitor status in severe hemophilia A patients treated with the double virus inactivated FVIII concentrate Haemoctin® SDH. Haemophilia 1996;2: (suppl 1), Abstract 404.
20. Rossi R, Albrecht O, Pollmann H, Jorch G, Harms E. Effect of a reduced vitamin K supplementation on prothrombin time in prematures and high-risk neonates. Acta Paediatrica 1996;85(6):747-749.
21. Tavassoli K, Eigel A, Pollmann H, Horst J. Mutational analysis of ectopic factor VIII transcripts from hemophilia A patients: identification of cryptic splice site, exon skipping and novel point mutations. Human Genetics 1997;100(5-6):508-511.
22. Nowak-Göttl U, Debus O, Findeisen M, Kassenböhmer R, Koch HG, Pollmann H, Postler C, Weber P, Vielhaber H. Lipoprotein (a): its role in childhood thromboembolism. Pediatrics 1997;99(6):E11.
23. Pollmann H, Eberl W, Bendix M, Wendisch J, Kreuz W, Barthels M, Herrmann F, Prager S, Haubold E, Schröder W, Wenzel E, Lenk H, Bratanoff B, Scheel H, Hempelmann L, Wulff K, Wollina K, Niekrenz C, Bergmann F, Schmeltzer B, Kirsten K, Aumann V, Zeitler P. Genomische Diagnostik in deutschen Familien mit Hämophilie B. Von der RFLP- Analyse zum Mutationsnachweis. In: I. Scharrer, W. Schramm (Hrsg) Berlin,Heidelberg,New York: Springer 1998, 340-343.
24. Pollmann H. Why do hemophiliacs bleed? Der Internist 1998;39(1):91.
25. Bendix M, Schröder W, Wulff K, Aumann V, Barthels M, Bratanoff B, Bergmann F, Eberl W, Haubold E, Hempelmann L, Kirsten K, Kreuz W, Lenk H, Niekrenz C, Pollmann H, Prager S, Scheel H, Schmeltzer B, Wendisch J, Wenzel E, Wollina K, Zeitler P, Herrmann FH. Genomische Diagnostik in deutschen Familien mit Hämophilie B. Von der RFLP-Analyse zum Mutationsnachweis. In: Scharrer I, Schramm W (Hg.): 27. Hämophilie-Symposion Hamburg 1996. Springer-Verlag, Berlin Heidelberg 1998, S. 340-343.
26. Tavassoli K, Eigel A, Wilke K, Pollmann H, Horst J. Molecular diagnostics of 15 hemophilia A patients: characterization of eight novel mutations in the factor VIII gene, two of which result in exon skipping. Human Mutation 1998;12(5):301-303.
27. Pollmann H, Richter H, Jürgens H. Platelet dysfunction as the cause of spontaneous bleeding in two haemophilic patients taking HIV protease inhibitors. Thrombosis and Haemostasis 1998;79(6):1213-1214.
28. Pollmann H, Richter H, Ringkamp H, Jürgens H: When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. European Journal of Pediatrics 1999;158 Suppl 3:166-170.
29. Möller-Morlang K, Tavassoli K, Eigel A, Pollmann H, Horst J. Mutational-screening in the factor VIII gene resulting in the identification of three novel mutations, one of which is a donor splice mutation. Mutations in brief no. 245. Online. Human Mutation 1999;13(6):504.
30. Pollmann H, Aledort L. Albumin-free formulated recombinant factor VIII preparations - How big a step forward? Thrombosis and Haemostasis 1999;82(4):1370-1371.
31. Möller-Morlang K, Tavassoli K, Eigel A, Pollmann H, Horst J. Mutational screening in the factor VIII gene resulting in the identification of three novel mutations, one of which is a donor splice mutation. Human Mutation 1999;13(6):504.
32. Halimeh S, Richter H, Ringkamp H, Pollmann H. Hemoglobin (Hb) and mean corpuscular hemoglobin (MCH) in childhood patients with severe hemophilia A. 43. Jahrestagung der Gesellschaft für Thrombose und Hämostaseforschung e.V. (GTH), Mannheim 1999.
33. Kotitschke R, Kloft M, Elödi S, Pollmann H, Behrmann M. Haemophilia A patients (previously treated, n > 50) without inhibitors, treated for 12 to 42 months with Haemoctin SDH (pd FVIII, double virus inactivated). 43. Jahrestagung der Gesellschaft für Thrombose und Hämostaseforschung e.V. (GTH), Mannheim 1999.
34. Herrmann FH, Wulff K, Auberger K, Aumann V, Bergmann F, Bergmann K, Bratanoff E, Franke D, Grundeis M, Kreuz W, Lenk H, Losonczy H, Maak B, Marx G, Mauz-Körholz C, Pollmann H, Serban M, Sutor A, Syrbe G, Vogel G, Weinstock N, Wenzel E, Wolf K. Molecular biology and clinical manifestation of hereditary factor VII deficiency. Seminars in Thrombosis and Hemostasis 2000;26(4):393-400 (Review).
35. Pollmann H, Huppertz-Helmhold S. First results from 60 hemophilia A patients enrolled in a German pharmacovigilance evaluation with ReFacto®. Blood 2000;96(suppl 1):261a. Abstract 1124.
36. Pollmann H, Richter H and the rFVIII-SQ Study Group. Results of a five-year clinical study with a B-domain dleted FVIII concentrate (rFVIII-SQ). In: I. Scharrer, W. Schramm (Eds.) 31st Hemophilia Symposion Hamburg 2000 (published by Springer-Verlag, Berlin Heidelberg 2002)
37. Fromme A, Dreeskamp K, Pollmann H, Mooren FC, Thorwesten L, Völker K. Aspekte des Bewegungs- und Sportverhaltens von Hämophilie-Patienten. Deutsche Zeitschrift für Sportmedizin 2001:7-8.
38. Escuriola-Ettingshausen C, Halimeh S, Kurnik K, Schobess R, Wermes C, Junker R, Kreuz W, Pollmann H, Nowak-Göttl U. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thrombosis and Haemostasis 2001;85(2):218-220.
39. Pollmann H, Huppertz-Helmhold S. and the German ReFacto Pharmacovigilance Data Monitoring Board. Comparison of prophylaxis and on-demand treatment of hemophilia A patients treated with Refacto. Abstract 201. 45. Jahrestagung der Gesellschaft für Thrombose und Hämostaseforschung e.V. (GTH), Düsseldorf 2001.
40. Herrmann FH, Wulff K, Lopaciuk S, Pollmann H. Greifswald registry of factor X congenital deficiency - first report on gene diagnosis of families with FX deficiency. Abstract 90. 45. Jahrestagung der Gesellschaft für Thrombose und Hämostaseforschung e.V. (GTH), Düsseldorf 2001.
41. Pollmann H, Richter H, Dreeskamp K, Voelcker L. Hemophilia and sport. Supplement to the journal Thrombosis and Haemostasis, July 2001, Abstract P1093, Poster.
42. Pollmann H, Huppertz-Helmhold S and the German ReFacto® Pharmacovigilance Data Monitoring Board. One year results from hemophilia A patients enrolled in a German pharmacovigilance evaluation with Refacto®. Supplement to the journal Thrombosis and Haemostasis, July 2001, Abstract P2560, Poster.
43. Herrmann FH, Wulff K, Lopaciuk S, Pollmann H. Two novel factor X gene mutations in severe factor X deficiency – Greifswald registry of factor X deficiency. Supplement to the journal Thrombosis and Haemostasis, July 2001, Abstract: P1126, Poster.
44. Bogdanova N, Lemcke B, Markoff A, Pollmann H, Dworniczak B, Eigel A, Horst J. Seven novel and four recurrent point mutations in the factor VIII (F8C) gene. Human Mutation 2001;18(6):546.
45. Bogdanova N, Lemcke B, Markoff A, Pollmann H, Dworniczak B, Eigel A, Horst J. Seven novel and four recurrent point mutations in the factor VIII (F8C) gene. Human Mutation 2002;19(1):84.
46. Pollmann H, Richter H. Status of infection in young hemophilia patients in Münster. Seminars in Thrombosis and Hemostasis 2002;28 Suppl 1:47-50, (Review).
47. Bogdanova N, Markoff A, Pollmann H, Nowak-Göttl U, Eisert R, Dworniczak B, Eigel A, Horst J. Prevalence of small rearrangements in the factor VIII gene F8C among patients with severe hemophilia A. Human Mutation 2002;20:236-237.
48. Siegmund B, Richter H, Pollmann H. Prophylactic treatment of afibrinogenemia with fibrinogen concentrate Haemocomplettan®. Abstract T12-130. 16th International Congress on Fibrinolysis and Proteolysis in conjunction with the 17th International Fibrinogen Workshop, München 2002
49. Ettingshausen CE, Kurnik K, Schobess R, Kreuz WD, Halimeh S, Pollmann H, and Nowak-Göttl U. Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease. Blood 99:1499-1500, 2002.
50. Pollmann H. Quality assurance in hemophilia A therapy: A pharmacovigilance evaluation with Refacto® in Germany – 3 years of experience. GTH 2002, Erfurt, Poster.
51. Pollmann H, Huppertz-Helmhold S. Comparison of prophylaxis and on-demand treatment: Evaluation derived from the German pharmacovigilance evaluation with Refacto®. GTH 2002, Erfurt, Poster.
52. Pollmann H, Huppertz-Helmhold S and Refacto Pharmacovigilance Data Monitoring Board. The importance of pharmacovigilance Haemophilia (2002), 8: 575, Abstract 20PO32. Poster, WFH Sevilla 2002.
53. Halimeh S, Bogdanova N, Eigel A, Abshagen K, Pollmann H, Jürgens H. Incidence of clinical relevant inhibitor development and MRI-documented joint damage in consecutively recruited severe haemophilia A and B patients: time for changing a therapeutic regimen. Haemophilia (2002), 8: 474, Abstract 01PO39. Poster, WFH Sevilla 2002.
54. Richter H, Siegmund B, Pollmann H. Afibrinogenemia: Prophylactic Treatment with Fibrinogen Concentrate Haemocomplettan®. Blood 2002, 100 (11): 494a, Abstract 1924, ASH 2002, Philadelphia.
55. Pollmann H, Huppertz-Helmhold S and the German Data Monitoring Board. Inhibitor Development in PUPs with Hemophilia A Treated with rFVIII: Data Derived from the German Pharmacovigilance Evaluation with ReFacto®. Blood 2002, 100 (11): 494a, Abstract 2749, ASH 2002, Philadelphia.
56. Herrmann F, Wulff K, Lopaciuk S, Pollmann H. Greifswald Registry of Factor X Congenital Deficiency - Two Novel Factor X Gene Mutations in Severe FX Deficiency: Gly222Asp and Ser379Lys. In: F.H. Herrmann (Hrsg) Gene Diagnosis of Inherited Bleeding Disorders. Lengerich, Berlin, Bremen: Pabst Science Publishers 2002, 182-192.
57. Nowak-Göttl U, Escuriola C, Kurnik K, Schobess R, Horneff S, Kosch A, Kreuz W, Pollmann H. Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations? Hämostaseologie 2003;23(1):36-40.
58. Siegmund B, Richter H, Pollmann H. Prophylactic treatment of afibrinogenemia with the fibrinogen concentrate Haemocomplettan® Journal of Thrombosis and Haemostasis 2003;1 Suppl 1, Abstract.
59. Siegmund B, Richter H, Pollmann H. Afibrinogenemia: Prophylactic treatment with fibrinogen concentrate Haemocomplettan? 47th Annual Meeting of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung, Insbruck 2003. Annals of Hematology. 2003, Abstract 288, S82, Poster.
60. Pollmann H, Huppertz-Helmhold S and Data Monitoring Board German Refacto PE. Assessment of the inhibitor development in previously untreated patients (PUPs) suffering from hemophilia A treated with rFVIII: continuous evaluation of the German Pharmacovigilance Evaluation (PE) with ReFacto. J Thromb Haemost. 2003 Supplement, Abstract: P0646, Poster.
61. Pollmann H, Huppertz-Helmhold S. Inhibitor development in PUPs with haemophilia A treated with rFVIII: Data derived from the German Pharmacovigilance Evaluation (PE) with ReFacto. Annals of Hematology. 2003, Abstract 234, S69, Poster.
62. Mondorf W, Pollmann H, Hense M. Evaluation of a 'handheld' communicator based electronic system for documentation of hemophilia A and B therapy in home-care settings. J Thromb Haemost. 2003 Supplement, Abstract: P1649, Poster.
63. Mondorf W, Eifrig B, Ellbrück D, Kalnins W, Kirchmaier CM, Oestreicher P, Pollmann H, Siemens A, Zimmermann R, Hense M. Selfevaluation of the German haemophilia cohort, results of a multicentre questionnaire. Annals of Hematology 2003, Abstract 215, S64, Poster.
64. Mondorf W, Pollmann H, Hense M. Evaluation of a 'handheld' communicator based electronic system for documentation of hemophilia A and B therapy in homecare settings. Annals of Hematology 2003, Abstract 216, S64, Poster.
65. Wulff K, Schröder W, Pollmann H, Glenschek C, Herrmann FH. Molecular genetic variations in the 5 flanking region of the FVII gene. Annals of Hematology. 2003, Abstract 336, S95, Poster.
66. Von Auer C, Oldenburg J, Auerswald G, Von Depka-Prodzinski M, Eifrig B, Escuriola-Ettinghausen C, Heinrichs C, Klamroth R, Kreuz W, Kurnik K, Lenk H, Pollmann H, Siegmund B, Syrbe G, Varvenne M, Wolf HH, Zimmermann R, Scharrer I. The development of inhibitors directed against factor VIII after continuous infusion of factor VIII concentrates in patients with hemophilia A. J Thromb Haemost. 2003 Supplement, Abstract: P1623, Poster.
67. Siegmund B, Richter H, Pollmann H. Quality check and validation of common isolated shipping systems used by the pharmaceutical industries for cooling of blood products. Journal of Thrombosis and Haemostasis 2003 Supplement, Abstract: P1609, Poster.
68. Herrmann F, Wulff K, Lopaciuk S, Pollmann H. Gly222Asp and Ser379Lys - Novel Factor X Gene Mutations in severe FX Deficiency - Greifswald Registry of Factor X congenital Deficiency. In: I.Scharrer/W.Schramm (Hrsg) 32. Hämophilie-Symposion Hamburg 2001. Berlin, Heidelberg: Springer Verlag 2003, 49-57.
69. Pollmann H, Richter H, Siegmund B. Comparative effectiveness of plasma-derived and recombinant FVIII concentrates in the on-demand and prophylactic treatment of patients with haemophilia A. Haemophilia 2004;10(5),676-678.
70. Pollmann H, Richter H, Siegmund B. Effectiveness of plasma derived and recombinant FVIII concentrates during on demand and prophylactic treatment, a comparative retrospective study. Hämostaseologie 2004, 24: A46, Abstract P29, Poster.
71. Mondorf W, Pollmann H, Hense M. First results and experience from a 'Handheld' Communicator based electronic system for documentation of hemophilia A and B therapy in homecare settings. Hämostaseologie 2004, 24: A68, Abstract P115, Poster.
72. Pollmann H and the ReFacto Pharmacovigilance Data Monitoring Board. Evaluation of the pharmacovigilance evaluation with ReFacto®: Commitment to monitor a recently licensed product under routine conditions in a post marketing surveillance evaluation. Hämostaseologie 2004, 24: A68, Abstract P116, Poster.
73. Pollmann H and the ReFacto Pharmacovigilance Data Monitoring Board. Evaluation of the pharmacovigilance evaluation with ReFacto®: Update on hemophilia A patient cohort, treatment regime and assessment of therapy. Hämostaseologie 2004, 24: A68, Abstract P117, Poster.
74. Mondorf W, Eifrig B, Ellbrück D, Kalnins W, Kirchmaier CM, Klamroth R, Oestreicher P, Pollmann H, Siemens A, Zimmermann R, Hense M. Selfevaluation of patients with severe haemophilia A, B and vWD - major differences in young and old according to a multicentre questionnaire. Hämostaseologie 2004, 24: A69, Abstract P121. Poster
75. Siegmund B, Richter H, Pollmann H. Quality check and validation of common isolated shipping systems used by the pharmaceutical industries for cooling of blood products. Hämostaseologie 2004, 24: A87, Abstract P191, Poster.
76. Pollmann H, Externest D. Pharmacovigilance evaluation with ReFacto. Haemophilia 2004, 10(3): 11. Abstract 02PO39, Poster.
77. Siegmund B, Richter H, Pollmann H. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits? Haemophilia 2005;11(6):638–641.
78. Smith M P, Giangrande P, Pollmann H, Littlewood R, Kollmer C, Feingold J, the Refacto St Louis Study Group. A postmarketing surveillance study of the safety and efficacy of ReFacto® (St Louis-derived active substance) in patients with haemophilia A. Haemophilia 2005;11(5):444ff.
79. Bogdanova N, Markoff A, Pollmann H, Nowak-Göttl U, Eisert R, Wermes C, Todorova A, Eigel A, Dworniczak B, Horst J. Spectrum of molecular defects and mutation detection rate in patients with severe hemophilia A. Human Mutation 2005;26(3):249-254.
80. Pollmann H, Externest D and the Refacto Data Monitoring Board. Pharmacovigilance Evaluation with ReFacto®– 6 years Post-Licensure Experience With ReFacto®– Recombinant Factor VIII – in Germany and Austria. Journal of Thrombosis and Haemostasis 2005;3(1) Abstract P2020, Poster.
81. Herrmann FH, Auerswald G, Ruiz-Saez A, Navarette M, Pollmann H, Lopaciuk S, Batorova A, Wulff K for the Greifswald Factor X Deficiency Study Group. Factor X Deficiency: Clinical Manifestation of 102 Subjects with Mutations in Factor 10 Gene. Journal of Thrombosis and Haemostasis 2005; 3(1) Abstract P1447, XXth Congress, 6.-12. August 2005, Sydney, Australia.
82. Mondorf W, Pollmann H. Home Treatment Diaries: Evaluation of a Handheld Communicator Brand Electronic System for the Documentation of Hemophilia Therapy. Journal of Thrombosis and Haemostasis 2005; 3(1) Abstract P0831, Poster.
83. Siegmund B, Pollmann H. ADVOY: First Experiences with an Internet Based Electronic System for Documentation of Haemophilia Therapy of Patients in Home Treatment. Journal of Thrombosis and Haemostasis 2005; 3(1) Abstract P2077, Poster.
84. Pavlova A, Luxembourg B, Geisen C, Watzka M, Lim-Eimer M, Lindhoff-Last E, Kreuz W, Klamroth R, Pollmann H, Seifried E, Oldenburg J. Mutation detection in patients with inherited antithrombin, protein C and protein S deficiency. Hämostaseologie 2005; A22, Abstract V47, Vortrag.
85. Siegmund B, Pollmann H. First experiences with ADVOY, an internet based electronic system for documentation of haemophilia therapy of patients in home treatment Hämostaseologie 2005; Abstract L1, Poster.
86. Pollmann H, Externest D. Pharmacovigilance Evaluation with ReFacto® - 5 year data on patient cohort and inhibitor development in haemophilia A patients treated with recombinant factor VIII under post-marketing Conditions. Hämostaseologie 2005; A76, Abstract P123, Poster.
87. Herrmann FH, Auerswald G, Ruiz-Saez A, Navarrete M, Pollmann H, Lopaciuk S, Batorova A, Wulff K, CA: The Greifswald Factor X Deficiency Study Group. Factor X deficiency: Clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia 2006;12(5):479-489.
88. Kellinghaus C, Wibbeke B, Evers S, Reichelt D, Pollmann H, Husstedt IW. Neurophysiological abnormalities in HIV-infected long term survivors. European Journal of Medical Research 2006;11(6):245-249.
89. Herrmann F, Wulff K, Auerswald G, Pollmann H, Kreuz W. Factor FVII deficiency: clinical manifestation and molecular genetics of more than 650 subjects with FVII gene mutations. Haemophilia 2006, 12(2), 75, Abstract 17FP486.
90. Pollmann H, Externest D. Pharmacovigilance evaluation with ReFacto – 6 year experience with ReFacto, recombinant factor VIII. Haemophilia 2006, 12(2), 19, Abstract 05PO115, Poster.
91. Mondorf W, Pollmann H. A new monitoring approach for physicians and patients: from documentation to health care management in hemophilia therapy. Haemophilia 2006, 12(2), 32, Abstract 07PO207, Poster.
92. Morfini M, Haya S, Pollmann H, Siegmund B, Stieltjes N, Dolan G, Ludlam C. European Study on Orthopedic Status (ESOS) of haemophilia patients with inhibitors: preliminary observations. Haemophilia 2006, 12(2), 64, Abstract 14PO406, Poster.
93. Mondorf C, Mondorf W, Kalnins W, Pollmann H, Eifrig B, Zimmermann R. Prophylactic vs. on demand treatment in severe haemophilia A and B – results of a German multicenter patient self-evaluation. Haemophilia 2006, 12(2), 108, Abstract 23PO710, Poster.
94. Siegmund B, Richter H, Pollmann H. Von-Willebrand-Syndrome within the collective of haemophilic patients as reason for unexpected bleeding episodes. Haemophilia 2006, 12(2), 141, Abstract 30PO913, Poster.
95. Mondorf W, Kalnins W, Eifrig B, Kirchmaier C, Pollmann H, Siemens H. A study to assess patient opinions of choice, safety and efficacy of treatment of hemophilia A. Haemophilia 2006, 12(2), 18, Abstract 05PO109, Poster.
96. Geisen C, Rost S, Spohn G, Fregin A, Watzka M, Dimichele DM, Haubelt H, Heistinger M, Kadar JG, Kemkes-Matthes B, Lages P, Lindhoff-Last E, Luxembourg B, Pollmann H, Zimmermann R, Müller CR, Seifried E, Oldenburg J. Various missense mutations in the vitamin K epoxide reductase complex subunit 1 (VKORC1) cause hereditary coumarin resistance. Hämostaseologie 2006; 26. Abstract P097. Poster.
97. Siegmund B, Richter H, Pollmann H. Das Von-Willebrand-Syndrom im Kollektiv hämophiler Patienten als mögliche Ursache unerwarteter Blutungsereignisse. Hämostaseologie 2006; 26, Abstract P173, Poster
98. Mondorf W, Pollmann H. Quality assurance in hemophilia therapy by a new monitoring approach for physicians and patients: from documentation to health care management. Hämostaseologie 2006; 26, Abstract P177, Poster.
99. Herrmann FH, Wulff K, Auerswald G, Pollmann H. Faktor VII Mangel: klinische Manifestation und molekulare Genetik von 664 Trägern von FVII Genmutationen. Hämostaseologie 2006; 26(1), Abstract P262. Poster.
100. Pollmann H, Externest D and the ReFacto® Pharmacovigilance Data Monitoring Board. Pharmacovigilance evaluation with ReFacto® - 6-year experience with ReFacto®, recombinant factor VIII. Hämostaseologie 2006; 26, Abstract P327. Poster
101. Bogdanova N, Markoff A, Eisert R, Wermes C, Pollmann P, Todorova A, Chlystun M, Nowak-Göttl U, Horst J. Spectrum of molecular defects and mutation detection rate in patients with mild and moderate hemophilia A. Human Mutation 2007;28(1):54-60.
102. Siegmund B, Richter H, Pollmann H. Von Willebrand disease within the collective of haemophilic patients as reason for unexpected bleeding episodes. Haemophilia. 2007;13(1):21-25.
103. Pollmann H, Externest D, Ganser A, Eifrig B, Kreuz W, Lenk H, Pabinger I, Schramm W, Schwarz TF, Zimmermann R, Zavazava N, Oldenburg J, Klamroth R. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 2007;13(2):131-143.
104. Di Paola J, Smith MP, Klamroth R, Mannucci PM, Kollmer C, Feingold J, Kessler C, Pollmann H, Morfini M, Udata C, Rothschild C, Hermans C, Janco R. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia 2007;13(2):124-130.
105. Fromme A, Dreeskamp K, Pollmann H, Thorwesten L, Mooren FC, Völker K. Participation in sports and physical activity of haemophilia patients. Haemophilia 2007;13(3):323-327.
106. Morfini M, Haya S, Tagariello G, Pollmann H, Quintana M, Siegmund B, Stieltjes N, Dolan G, Tusell J. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007;13(5):606-612.
107. Geisen C, Sittinger K, Spohn G, Dimichele DM, Haubelt H, Heistinger M, Kadar JG, Kemkes-Matthes B, Klamroth R, Lages P, Lindhoff-Last E, Luxembourg B, Mansouri Taleghani B, Pollmann H, Spannagl M, Zimmermann R, Seifried E, Oldenburg J. Seven novel missense mutations in the vitamin K epoxide reductase complex subunit 1 (VKORC1) cause hereditary coumarin resistance. Journal of Thrombosis and Haemostasis 2007; 5(2), P-M-506.
108. Mondorf W, Pollmann H. Final results of a feasibility study on an electronic monitoring system in hemophilia care. Journal of Thrombosis and Haemostasis 2007; 5(2), P-T-143.
109. Pollmann H and the ReFacto Pharmacovigilance Data Monitoring Board. Seven years pharmacovigilance evaluation with Refacto: inhibitor development in previously treated and untreated hemophilia A patients. Journal of Thrombosis and Haemostasis 2007; 5(2), P-W-123.
110. Siegmund B, Richter H, Pollmann H. On demand treatment and continuous prophylaxis of adult haemophilia A patients: a comparative retrospective data ascertainment. Journal of Thrombosis and Haemostasis 2007; 5(2) Abstract P-W-132. Poster.
111. Wieland I, Wermes C, Eifrig B, Hollstein K, Pollmann H, Siegmund B, Bidlingmaier C, Kurnik K, Nimtz-Talaska A, Niekrens C, Eisert R, Tiede A, Ebenebe C, Lakomek M, Welte K, Sykora KW. Report to the inhibitor-immunology-study. Hämostaseologie 2007; 27, P096. Abstract, Poster.
112. Pollmann H for the ReFacto Pharmacovigilance Data Monitoring Board. Efficacy and safety of ReFacto®: Results of seven years pharmacovigilance evaluation. Hämostaseologie 2007; 27, P100. Abstract, Poster.
113. Mondorf W, Pollmann H. Interim results of a feasibility test on an electronic monitoring system in hemophilia care. Hämostaseologie 2007; 27, P114. Abstract, Poster.
114. Siegmund B, Richter H, Pollmann H. Haemophilia A therapy in adulthood: Experiences of a German haemophilia centre. Hämostaseologie 2007; 27, P117. Abstract, Poster.
115. Herrmann FH, Wulff K, Auerswald G, Astermark J, Batorova A, Kreuz W, Pollmann H, Ruiz-Saez A, Salazar-Sanchez L, Schulman S and International Study Group of Greifswald Registry FVII Deficiency. Factor VII deficiency: Clinical manifestation and molecular genetics of subjects (718) with FVII gene mutations - Update 2006 of the International Greifswald Registry of congenital FVII deficiency. Hämostaseologie 2007; 27, P191. Abstract, Poster.
116. Mondorf W, Eifrig B, Franke D, Kadar J, Kalnins W, Kirchmaier C, Klamroth R, Pollmann H, Schulz U, Syrbe G, Zimmermann R, Qualitätszirkel Haemostaseologie. Results of a multicenter selfevaluation among adult patients with severe haemophilia in Germany - influence of on demand vs. prophylactic treatment in childhood. Hämostaseologie 2007; 27, FV18.
117. Siegmund B, Richter H, Pollmann H. Bleeding frequency during continuous prophylaxis of haemophilia A patients in adulthood. Hämostaseologie 2007; 27, FV34.
118. Berntorp E, Archey W, Auerswald G, Federici Augusto A B, Franchini M, Knaub S, Kreuz W, Lethagen S, Mannucci P M, Pollmann H, Scharrer I, Hoots K. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: History and clinical performance. European Journal of Haematology 2008;Suppl 70:3–35, Review.
119. Siegmund B, Richter H, Pollmann H. Prevalence of genetic and acquired markers in the collective of patients with suspected thrombophilia. Hämostaseologie 2008; 28, A67. Abstract, Poster P-08-03.
120. Siegmund B, Orlovic M, Gottstein S, Richter H, Klamroth R, Pollmann H. Inhibitor development and efficacy of plasma-derived and recombinant factor VIII concentrates in previously treated patients with severe haemophilia A. Hämostaseologie 2008; 28, A110. Abstract, Poster P-26-03.
121. Mondorf W, Klamroth R, Siegmund B, Weise B, Westfeld M, Galler A, Pollmann H. HaemoassistTM – mobile patient diary improves the home treatment monitoring. Hämostaseologie 2008; 28, A105. Abstract, Poster P-24-01.
122. Pollmann H. Safety and efficacy of ReFacto® in previously untreated haemophilia A patients – results of eight years of pharmacovigilance evaluation. Hämostaseologie 2008; 28, A107. Abstract, Poster P-24-10.
123. Wieland I, Wermes C, Eifrig B, Holstein K, Pollmann H, Siegmund B, Nimtz-Talaska A, Niekrens C, Ebenebe C, Tiede A, Hoy L, Sykora KW. Inhibitor-Immunology-Study: Role of the HLA-type in the inhibitor development of haemophilia A. Hämostaseologie 2008; 28, A42. Abstract, Poster P-01A-09.
124. Siegmund B, Richter H, Pollmann H, Orlovic M, Gottstein S, Klamroth R. Inhibitor development and efficacy of recombinant vs. plasma-derived factor VIII concentrates in haemophilia A patients. Haemophilia 2008, 14(2), 51. Abstract, Poster 08PO56.
125. Pollmann H for the Refacto pharmacovigilance data monitoring board. Eight years of pharmacovigilance evaluation with ReFacto - safety and efficacy in previously untreated haemophilia A patients. Haemophilia 2008, 14(2), 52. Abstract, Poster 08PO59.
126. Pavlova A, Brondke H, Müsebeck J, Pollmann H, Srivastava A, Oldenburg J. Molecular genetic mechanisms of haemophilia A in females. Haemophilia 2008, 14(2), 61. Abstract, Poster 09PO17.
127. Mondorf W, Klamroth R, Siegmund B, Westfeld M, Galler A, Pollmann H. The electronic patient diary haemoassist improves home treatment monitoring. Haemophilia 2008, 14(2), 138. Abstract, Poster 25PO18.
128. Westfeld M, Kosch M, Pollmann H, Huth-Kühne A, Eisert R, Laws HJ, Niekrens C, Girisch G, Severin K, Ries M, Oldenburg J. Evaluation of safety and efficacy of recombinant Factor IX in daily clinical practice: a pharmacovigilance evaluation of BeneFIX. 41. Jahreskongress der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI), 16. Kongress der Interdisziplinären Europäischen Gesellschaft für Hämapherese und Hämotherapie (ESFH) in Düsseldorf, 2008. Poster.
129. Westfeld M, Oldenburg J, Pollmann H, Kosch M. Evaluation of safety and efficacy of recombinant Factor IX in daily clinical practice: a pharmacovigilance evaluation of BeneFIX. Jahrestagung der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO), Wien 2008. Poster.
130. Wiedebusch S, Pollmann H, Siegmund B, Muthny FA. Quality of life, psychosocial strains and coping in parents of children with haemophilia. Haemophilia 2008;14:1014–1022.
131. Herrmann F, Wulff K, Auerswald G, Astermark J, Aumann V, Batorova A, Bergmann F, Eifrig B, Eisert R, Franke D, Goebel U, Heller C, Kreuz W, Kurnik K, Lenk H, Loreth R M, Pollmann H, Ruiz-Saez A, de Bosch N, Salazar-Sanchez L, Schenk J, Schubert C, Schulmann S, Wendisch J, Vogel G. Klinische Manifestation bei congenitalem Faktor VII Mangel - Update des Greifswald-Registers Faktor-VII-Mangel -. In: Haemophilia and Rare Bleeding Disorders - Molecular Genetics, Molecular Pathology and Clinical Manifestation. 1. Aufl., Pabst Science Publishers 2008, 27-50.
132. Herrmann F, Wulff K, Auerswald G, Arlt M, Barthels M, Batorova A, Boadas A, de Bosch N, Bergmann F, Budde U, Eifrig B, Eisert R, Halimeh S, Hernandez C, Kentouche K, Kluba U, Kurnik K, Lopaciuk S, Maak B, Marx G, Mitulla B, Naumann B, Navarrete M, Carrillo J, Pfanner G, Pollmann H, Ruiz-Saez A, Salazar-Sanchez L, Scharrer I, Scharf E, Syrbe G, Depka Prondzinski M, Wendisch J, Wolf K. Klinische Manifestation bei congenitalem Faktor-X-Mangel - Update des Greifswald-Registers Faktor-X-Mangel -. In: Haemophilia and Rare Bleeding Disorders - Molecular Genetics, Molecular Pathology and Clinical Manifestation. 1. Aufl., Pabst Science Publishers 2008, 138-155.
133. Schröder W, Wulff K, Naumann B, Pollmann H, Herrmann F. Schwere intrakraniale Blutungen bei zwei Brüdern mit FX-Mangel – Charakterisierung einer homozygoten Acceptor splice site Mutation im FX-Gen. In: Herrmann FH (Ed.) Haemophilia and Rare Bleeding Disorders 2008. 1. Aufl., Pabst Science Publishers 2008, 156-164.
134. Wieland I, Wermes C, Eifrig B, Holstein K, Pollmann H, Siegmund B, Bidlingmaier C, Kurnik K, Nimtz-Talaska A, Niekrens C, Eisert C, Tiede A, Ebenebe C, Lakomek M, Hoy L, Blaszcyk R, Welte K, Sykora K-W. Bericht zur Inhibitor-Immunologie-Studie. Jahrestagung der Ständigen Kommission der Pädiatrie der GTH in Tübingen. Hämostaseologie 4, 2008, A123.
135. Wieland I, Wermes C, Eifrig B, Holstein K, Pollmann H, Siegmund B, Bidlingmaier C, Kurnik K, Nimtz-Talaska A, Niekrens C, Eisert C, Tiede A, Ebenebe C, Lakomek M, Hoy L, Blaszcyk R, Welte K, Sykora K-W. Inhibitor-Immunology-Study. Different HLA-types seem to be involved in the inhibitor development in haemophilia A. 38. Hamburger Hämophilie-Symposion. Hämostaseologie 2008;28 Suppl 1:26-28.
136. Schröder W, Naumann B, Pollmann H, Herrmann FH, Wulff K. Molecular characterization of the novel FX mutation IVS7-1G>A. 38. Hamburger Hämophilie-Symposion. Hämostaseologie 4a, 2008,28(1):103-104.
137. Herrmann FK. Wulff K, Auerswald G, Schulman S, Astermark J, Batorova A, Kreuz W, Pollmann H, Ruiz-Saez A, de Bosch N, Salazar-Sanchez L, for the Greifswald Factor FVII Deficiency Study group. Factor VII Deficiency: Clinical manifestation of 717 subjects from Europe and Latin America with mutations in the Factor 7 gene. Haemophilia 2009;15(1):267-280.
138. Siegmund B, Mondorf W, Klamroth R, Westfeld M, Galler A, Pollmann H. Telemedizin in der Hämophilie: Haemoassist – ein elektronisches Tagebuch zur Therapieoptimierung. In: Jäckel (Hrsg.) Telemedizinführer Deutschland, Bad Nauheim, Ausgabe 2009:170-173.
139. Siegmund B, Richter H, Pollmann H. D-Dimer as guiding parameter for LMWH prophylaxis: Therapeutic outcome of patients with thrombophilia and thrombotic history treated with LMWH during pregnancy. Hämostaseologie 2009, 29: A84. Abstract, Poster.
140. Siegmund B, Richter H, Pollmann H. Consumption of recombinant FIX compared to plasma derived FIX is increased in on demand and prophylactic treated patients with severe haemophilia B. Hämostaseologie 2009, 29: A42. Abstract, Poster.
141. Siegmund B, Richter H, Pollmann H. Impressive reduction of bleeds in patients with severe haemophilia B by prophylaxis requires a 3fold higher FIX consumption: A retrospective data analysis. Hämostaseologie 2009, 29: A39. Abstract, Poster.
142. Siegmund B, Richter H, Pollmann H, Orlovic M, Gottstein S, Klamroth R. Inhibitor development and efficacy of recombinant versus plasma-derived factor VIII concentrates in haemophilia A patients, an update. Hämostaseologie 2009, 29: A40. Abstract, Poster.
143. Westfeld M, Pollmann H, Laws HJ, Huth-Kühne A, Niekrens C, Girisch M, Ries M, Oldenburg J. Evaluation of safety and efficacy of recombinant Factor IX in daily clinical practice: a pharmacovigilance evaluation of BeneFIX. Hämostaseologie 2009, 29: A44. Abstract, Poster.
144. Mondorf W, Klamroth R, Siegmund B, Westfeld M, Pollmann H. Haemoassist™ – Implementation and challenges of an electronic patient diary in daily practical application. Hämostaseologie 2009, 29: A44. Abstract, Poster.
145. Pollmann H for the ReFacto® Pharmacovigilance Data Monitoring Board. Nine years of the ReFacto Pharmacovigilance evaluation – Safety and efficacy in daily clinical practice. Hämostaseologie 2009, 29: A43. Abstract, Poster.
146. Wieland I, Wermes C, Eifrig B, Bidlingmaier C, Pollmann H, Nimtz-Talaska A, Niekrens C, Sykora K. Inhibitor-Immunology-Study: Toll-like-receptor (TLR)-polymorphisms in the inhibitor development of haemophilia A. Hämostaseologie 2009, 29: A41. Abstract, Poster.
133. Mondorf W, Siegmund B, Mahnel R, Richter R, Westfeld W, Galler A, Pollmann H. HaemoassistTM – a hand-held electronic patient diary for haemophilia home care. Haemophilia 2009;15(2):464-472.
134. Siegmund B, Richter H, Pollmann H. Need for Prophylactic Treatment in Adult Haemophilia A Patients. Transfusion Medicine and Hemotherapy (Transfus Med Hemother) 2009;36:283–288
135. Pavlova A, Brondke H, Müsebeck J, Pollmann H, Srivastava A, Oldenburg J. Molecular mechanisms underlying haemophilia A phenotype in seven females. Journal of thrombosis and Haemostasis 2009;7(6):976-982.
136. Pollmann H. Was beschreibt ein Zentrum für Hämostaseologie? Expertenforum. Hämophilie – Perspektiven der Versorgung in Deutschland. Juni 2009, Nürnberg. Vortrag
137. Pollmann H. Final results of pharmacovigilance evaluation of B-domain-deleted recombinant Factor VIII – demonstrating safety and efficacy in more than 10 years. 54. Jahrestagung der Gesellschaft für Thrombose und Hämostaseforschung (GTH), 1. Joint Meeting GTH & NVTH, 2010, Nürnberg, FC 04-03.
138. Halimeh S, Eisert R, Klamroth R, Kirchmaier CM, Pollmann H, von Depka M, Auerswald G, Niekrens C, Girisch M, Gildberg PK, Gutsche S, Bassus S, Lampen P. NovoSeven® WIRK examination (Wirksamkeit im realen Klinikeinsatz) - non-interventional observational study in patients with congenital haemophilia with inhibitors, acquired haemophilia, Factor FVII deficiency, and Glanzmann‘s thrombasthenia. 54. Jahrestagung der Gesellschaft für Thrombose und Hämostaseforschung (GTH), 1. Joint Meeting GTH & NVTH, 2010, Nürnberg, P05-45.
139. Mondorf W, Klamroth R, Tuischer J, Westfeld M, Pollmann H, Scientific Board of the Haemoassist® Panel Germany. Haemoassist® - a useful tool for quality control in hemophilia care. 54. Jahrestagung der Gesellschaft für Thrombose und Hämostaseforschung (GTH), 1. Joint Meeting GTH & NVTH, 2010, Nürnberg, P06-35.
140. Westfeld M, Pollmann H, Oldenburg J, BeneFIX Pharmacovigilance Study Group. Non-interventional trial to assess the safety and efficacy of treatment with recombinant factor IX: interim analysis after two years of study duration. 54. Jahrestagung der Gesellschaft für Thrombose und Hämostaseforschung (GTH), 1. Joint Meeting GTH & NVTH, 2010, Nürnberg, P06-28.
141. Wieland I, Wermes C, Eifrig B, Holstein K, Pollmann H, Siegmund B, Eberl W, Fischer, Kemkes-Matthes B, Bidlingmaier C, Kurnik K, Lischetzki G, Nimtz-Talaska A, Eisert R, Dörk T, Sykora KW. Inhibitor-Immunology-Study: evaluation of different polymorphisms in the inhibitor development of haemophilia B. 54. Jahrestagung der Gesellschaft für Thrombose und Hämostaseforschung (GTH), 1. Joint Meeting GTH & NVTH, 2010, Nürnberg, P05-04.
142. Klamroth R, Siegmund B, Orlovic M, Gottstein S, Pollmann H. Reduced factor concentrate consumption during treatment of chronic hepatitis C in patients with haemophilia. 54. Jahrestagung der Gesellschaft für Thrombose und Hämostaseforschung (GTH), 1. Joint Meeting GTH & NVTH, 2010, Nürnberg, P06-31.
143. Siegmund B, Richter H, Pollmann H. Effectiveness of DDAVP (Minirin parenteral) in subjects with von Willebrand disease (VWD) type 1 and 2A. 54. Jahrestagung der Gesellschaft für Thrombose und Hämostaseforschung (GTH), 1. Joint Meeting GTH & NVTH, 2010, Nürnberg, P07-18.
144. Siegmund B, Mondorf W, Klamroth R, Westfeld M, Tuischer J, Pollmann H. Das Haemoassist®-System - Ein mobiles, elektronisches Therapietagebuch zur Verbesserung der Patientenführung und Therapieoptimierung in der Hämophilie. e-Health 2010, 134-137.
145. Siegmund B, Richter H, Pollmann H. Hämophilie-A-Therapie bei Erwachsenen - Situationsbericht aus einem Hämophilie-Behandlungszentrum. Hämostaseologie 2010; 30 (Suppl 1): S32-S34.
146. Siegmund B, Richter H, Pollmann H. Prophylaxe in der Hämophilie-B-Therapie – Reduktion der Blutungsfrequenz und FIX-Verbrauch. Hämostaseologie 2010; 30 (Suppl 1): S35-S36.
147. Siegmund B, Pollmann H, Richter H, Orlovic M, Gottstein S, Klamroth R. Inhibitorentwicklung bei FVIII-Präparaten in vorbehandelten Patienten mit Hämophilie A – Eine retrospektive Datenerhebung. Hämostaseologie 2010; 30 (Suppl 1): S37-S39.
148. Pollmann H, Siegmund B, Richter H. Schwere Hämophilie A: Wann werden Kinder diagnostiziert, wann beginnen sie zu bluten? – Aktualisierung nach 10 Jahren. Hämostaseologie 2010; 30 (Suppl 1): S112-S114.
149. Siegmund B, Pollmann H, Richter H, Orlovic M, Gottstein S, Klamroth R. Inhibitor development against factor VIII in previously treated patients with haemophilia A. Letter-to-the-editor, Hämophilia 2010, submitted.
150. Westfeld M, Mondorf W, Klamroth R, Siegmund B, Tuischer J, Pollmann H. An electronic documentation system in haemophilia provides otherwise unavailable feedback for continuous quality control – first results from the Haemoassist® System. XXIXth International Congress of the World Federation of Hemophilia 2010 Buenos Aires, Argentina, Poster 25P12.
151. Siegmund B, Richter H, Pollmann H. Effectiveness of DDAVP (Minirin Parenteral) in subjects with von Willebrand disease (VWD) type 1 and 2A. XXIXth International Congress of the World Federation of Hemophilia 2010 Buenos Aires, Argentina, Poster 35P43.
152. Westfeld M, Pollmann H for the Refacto® Pharmacovigilance Data Monitoring Board. Safety and efficacy of B-domain-deleted recombinant FVIII – final results of a 10-year pharmacovigiliance study. XXIXth International Congress of the World Federation of Hemophilia 2010 Buenos Aires, Argentina, Poster 07P18.
153. Westfeld M, Pollmann H, Oldenburg J. Two-year interim results of a non-interventional trial to assess the safety and efficacy of treatment with recombinant factor IX. XXIXth International Congress of the World Federation of Hemophilia 2010 Buenos Aires, Argentina, Poster 07P19.
154. Wieland I, Wermes C, Eifrig B, Holstein K, Pollmann H, Siegmund B, Eberl W, Fischer R, Kemkes-Matthes B, Bidlingmaier C, Kurnik K, Lischetzki G, Nimtz-Talaska A, Eisert R, Bogdanova N, Dörk T, Sykora K W. Inhibitor-Immunology-Study: Evaluation of inhibitor development in haemophilia B. 41. Hamburger Hämophilie-Symposion. 2010.
155. Siegmund B, Richter H, Pollmann H. Effectiveness of DDAVP (Minirin Parenteral) in subjects with Von Willebrand disease (VWD) Type 1 and 2A. 41. Hamburger Hämophilie-Symposion. 2010.
156. Klamroth R, Orlovic M, Gottstein S, Siegmund B, Pollmann H. Reduced factor concentrate consumption during treatment of chronic hepatitis C in patients with haemophilia. 41. Hamburger Hämophilie-Symposion. 2010.
157. Klamroth R, Pollmann H, Hermans C, Faradji A, Aaron SY, Epstein JD, Ewenstein BM. The Relative Burden of Hemophilia A and the Impact of Target Joint Development on Health-Related Quality of Life: Results from the ADVATE Post-Authorization Safety Surveillance (PASS) Study. Haemophilia 2011. Article first published online: 21 FEB 2011, DOI: 10.1111/j.1365-2516.2010.02435.x.
158. Wieland I, Wermes C, Eifrig B, Holstein K, Pollmann H, Siegmund B, Eberl W, Kemkes-Matthes B, Bidlingmaier C, Kurnik K, Lischetzki G, Nimtz-Talaska A, Eisert R, Bogdanova N, Hoy L, Blasczyk R, Sykora K-W. Inhibitor-Immunology-Study: Role of the HLA-type in the inhibitor development of haemophilia B. Hämostaseologie 2011; 31: A36, P01-11.
159. Pollmann H, Klamroth R, Kriukov AY, Epstein JD, Abraham I, Song CK, Luu HD, Oldenburg J. Post-approval, non-interventional study of safety, efficacy, and Health-Related Quality of Life (HRQOL) in patients with Hemophilia A (HA) treated with ADVATE rAHF-PFM in Germany. Hämostaseologie 2011; 31: A38, P02-11.
160. Siegmund B, Pollmann H. Effectiveness of DDAVP (Minirin parenteral) in subjects with thrombocytopathy. Hämostaseologie 2011; 31: A71, P11-15.
161. Siegmund B, Pollmann H. Biologische und klinische Ansprechbarkeit von Minirin parenteral bei Patienten mit VWD 1 VWD 2A und Thrombozytopathie. Hämostaseologie 2011, submitted.
